Sabitlenmiş Tweet
CBL-514.com (with and without the hyphen) is for sale.
CBL-514 is a first-in-class, injectable small-molecule drug that induces adipocyte apoptosis (targeted cell death) to reduce subcutaneous fat in specific areas.
As of January 2026, CBL-514 has emerged as the most significant breakthrough in the aesthetic and metabolic space since the rise of GLP-1s.
With Caliway's Phase 3 "SUPREME" trials currently underway and the newly launched Phase 2 weight-management studies (combining CBL-514 with tirzepatide/Zepbound), the term "CBL-514" is the global shorthand for the next generation of fat-loss technology.
The alphanumeric code "CBL-514" is the primary search term for patients, investors, and clinicians.
#CBL514
English
